CBD Policies From CHPA, CRN Follow FDA; AHPA Acts Ahead Of Agency
CHPA says FDA's enforcement discretion for hemp and CBD supplements isn't sufficient oversight as potentially unsafe products are available. CRN announces three CBD firms as members, but says "many companies marketing products as containing CBD are not" compliant. Guidance policy adopted in March says AHPA doesn't agree or disagree with FDA but some CBD firms and legal experts assert the agency is "inaccurate, and have presented certain arguments that potentially counter FDA’s position."
You may also be interested in...
With public hearing scheduled May 31 and a related public comment period, FDA "is interested in whether there are particular safety concerns that we should be aware of as we consider the FDA’s regulatory oversight and monitoring" of CBD products. Also influencing FDA's consideration is that CBD and other cannabis-derived substances are approved and being studied as drugs products, making their use as dietary ingredients noncompliant with agency regulations.
Senate Appropriations subcommittee members add to Capitol Hill's push for FDA to change its current regulatory stance that CBD is deemed noncompliant for use in supplements and food. Commissioner Gottlieb suggests legislation authorizing FDA to allow use of CBD up to certain concentrations in supplements and food products. FDA currently allows sales of food and supplements containing CBD under enforcement discretion.
Wellness Industry News: MacKay Leaving CRN; Another Life-Line Recall, Ginkgo Bioworks' Second Startup, More
Duffy MacKay is leaving CRN and Andrew Shao will return for an interim period; McDaniel Life-Line recalls all lots of its Life-Line Water due to contamination; Harvest One acquires LivRelief supplement firm; and Gingko Bioworks' second startup funded $90m.